Nucleoside analogues have been in clinical use for almost 50 years and have become
cornerstones of treatment for patients with cancer or viral infections. The approval of several …

Treatment of chronic hepatitis C virus (HCV) infection with direct-acting antiviral agents
(DAA) is associated with high rates of sustained virologic response. Remaining factors …

Aims A newly emerged Human Coronavirus (HCoV) is reported two months ago in Wuhan,
China (COVID-19). Until today> 2700 deaths from the 80,000 confirmed cases reported …

Background All-oral combination therapy is desirable for patients with chronic hepatitis C
virus (HCV) infection. We evaluated daclatasvir (an HCV NS5A replication complex inhibitor) …

The ProTide technology is a prodrug approach developed for the efficient intracellular
delivery of nucleoside analogue monophosphates and monophosphonates. In this …

The rapidly expanding Zika virus (ZIKV) epidemic has affected thousands of individuals with
severe cases causing Guillain-Barré syndrome, congenital malformations, and …

Hepatitis C virus (HCV) drug development has resulted in treatment regimens composed of
interferon‐free, all‐oral combinations of direct‐acting antivirals. While the new regimens are …

Nowadays, due to the development of potent Direct-Acting Antiviral Agents (DAAs) that
specifically target NS3, NS5A and NS5B viral proteins, several new and highly efficacious …

Hepatitis C currently infects more than 170 million people around the world, leading to
significant morbidity and mortality. The current standard of care for HCV infection, including …

Nucleotide analog inhibitors have shown clinical success in the treatment of hepatitis C virus
(HCV) infection, despite an incomplete mechanistic understanding of NS5B, the viral RNA …